WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that a NASDAQ Listing Qualifications Panel (“NASDAQ Panel”) has granted the Company’s request for continued listing of its securities on The NASDAQ Global Market. The Company’s continued listing is subject to the filing of the Company’s Form 10-K for the fiscal year ending December 31, 2007 on or before February 6, 2008, which evidences over $50 million in revenue and $50 million in total assets.
